CA3240327A1 - Methods of treating asthma with anti-light antibodies - Google Patents

Methods of treating asthma with anti-light antibodies Download PDF

Info

Publication number
CA3240327A1
CA3240327A1 CA3240327A CA3240327A CA3240327A1 CA 3240327 A1 CA3240327 A1 CA 3240327A1 CA 3240327 A CA3240327 A CA 3240327A CA 3240327 A CA3240327 A CA 3240327A CA 3240327 A1 CA3240327 A1 CA 3240327A1
Authority
CA
Canada
Prior art keywords
light
antibody
subject
light antibody
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3240327A
Other languages
English (en)
French (fr)
Inventor
Garry A. NEIL
H. Jeffrey Wilkins
Sheridan J. CARRINGTON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avalo Therapeutics Inc
Original Assignee
Avalo Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avalo Therapeutics Inc filed Critical Avalo Therapeutics Inc
Publication of CA3240327A1 publication Critical patent/CA3240327A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3240327A 2022-01-05 2023-01-04 Methods of treating asthma with anti-light antibodies Pending CA3240327A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263296786P 2022-01-05 2022-01-05
US63/296,786 2022-01-05
US202263396308P 2022-08-09 2022-08-09
US63/396,308 2022-08-09
PCT/US2023/060064 WO2023133389A2 (en) 2022-01-05 2023-01-04 Methods of treating asthma with anti-light antibodies

Publications (1)

Publication Number Publication Date
CA3240327A1 true CA3240327A1 (en) 2023-07-13

Family

ID=87074254

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3240327A Pending CA3240327A1 (en) 2022-01-05 2023-01-04 Methods of treating asthma with anti-light antibodies

Country Status (6)

Country Link
US (1) US20250002598A1 (enExample)
EP (1) EP4460523A4 (enExample)
JP (1) JP2025501865A (enExample)
AU (1) AU2023205910A1 (enExample)
CA (1) CA3240327A1 (enExample)
WO (1) WO2023133389A2 (enExample)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2484696B1 (en) * 2006-08-28 2017-08-16 Kyowa Hakko Kirin Co., Ltd. Antagonistic hLIGHT-specific human monoclonal antibodies
EP3750554A3 (en) * 2007-09-18 2021-07-28 La Jolla Institute for Allergy and Immunology Light inhibitors for asthma, lung and airway inflammation, respiratory, interstitial, pulmonary and fibrotic disease treatment
HK1257443A1 (zh) * 2015-08-21 2019-10-18 The Children's Hospital Of Philadelphia 治疗具有dcr3或dcr3网络基因中的遗传变异的患者的自身免疫病症的方法

Also Published As

Publication number Publication date
EP4460523A2 (en) 2024-11-13
US20250002598A1 (en) 2025-01-02
EP4460523A4 (en) 2025-12-17
AU2023205910A1 (en) 2024-06-06
WO2023133389A2 (en) 2023-07-13
JP2025501865A (ja) 2025-01-24
WO2023133389A3 (en) 2023-08-31

Similar Documents

Publication Publication Date Title
EP2627673B1 (en) Therapies for improving pulmonary function
JP2023162343A (ja) Ｉｌ－４ｒ拮抗薬の投与により喘息を処置または予防するための方法
JP2013544235A5 (enExample)
US20200095307A1 (en) Compositions and methods for the treatment of neuromyelitis optica
US20250002598A1 (en) Methods of Treating Asthma with Anti-LIGHT Antibodies
US20230279095A1 (en) Methods and Treatment for Adult-Onset Still's Disease and Systemic-Onset Juvenile Idiopathic Arthritis Involving Antibodies to IL-18
CN118488968A (zh) 用抗light抗体治疗哮喘的方法
HK40114122A (en) Methods of treating asthma with anti-light antibodies
US12331107B2 (en) Methods of treating pneumonia or respiratory failure associated with COVID-19 by administering an anti-LIGHT antibody
JP7343547B2 (ja) Ｉｌ－４ｒ拮抗薬の投与により喘息を処置または予防するための方法
AU2021479973A1 (en) Methods and treatment for adult-onset still's disease and systemic-onset juvenile idiopathic arthritis involving antibodies to il-18
TW202544036A (zh) 用抗ｔｓｌｐ抗體治療慢性阻塞性肺病
TW202613164A (zh) 以抗IL-1β抗體治療化膿性汗腺炎之方法
JP2023542521A (ja) ループス腎炎（ｌｎ）及び／又はｉｇａ腎症（ｉｇａｎ）を含むｃ５媒介性糸球体腎炎（ｇｎ）の治療のための抗ｃ５抗体の投与量及び投与
US20240158522A1 (en) Methods of Treating Ulcerative Colitis with Anti-LIGHT Antibodies
HK1188603A (en) Therapies for improving pulmonary function
HK1188603B (en) Therapies for improving pulmonary function

Legal Events

Date Code Title Description
P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS

Effective date: 20241113

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241211

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241211

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251205

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251215